Buck Wealth Strategies LLC Has $7.46 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Buck Wealth Strategies LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 13.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,899 shares of the medical research company’s stock after buying an additional 2,977 shares during the quarter. Amgen makes up about 2.8% of Buck Wealth Strategies LLC’s investment portfolio, making the stock its 15th largest holding. Buck Wealth Strategies LLC’s holdings in Amgen were worth $7,460,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Southland Equity Partners LLC raised its stake in Amgen by 2.3% during the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after buying an additional 34 shares during the period. Acropolis Investment Management LLC raised its position in shares of Amgen by 3.5% during the fourth quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock worth $288,000 after purchasing an additional 34 shares during the period. Opal Wealth Advisors LLC raised its position in shares of Amgen by 1.9% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock worth $538,000 after purchasing an additional 34 shares during the period. FORVIS Wealth Advisors LLC lifted its position in shares of Amgen by 1.4% in the fourth quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock worth $743,000 after purchasing an additional 35 shares in the last quarter. Finally, Evanson Asset Management LLC boosted its holdings in Amgen by 2.1% during the fourth quarter. Evanson Asset Management LLC now owns 1,666 shares of the medical research company’s stock worth $480,000 after purchasing an additional 35 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN traded down $6.83 on Tuesday, hitting $276.21. The company had a trading volume of 2,220,460 shares, compared to its average volume of 3,009,285. The firm has a 50 day moving average of $288.67 and a two-hundred day moving average of $281.34. The stock has a market capitalization of $148.03 billion, a price-to-earnings ratio of 22.38, a PEG ratio of 2.69 and a beta of 0.58. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGNGet Free Report) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter last year, the business posted $4.09 EPS. Amgen’s revenue for the quarter was up 19.8% on a year-over-year basis. On average, research analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.26%. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. The Goldman Sachs Group boosted their price target on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. SVB Leerink downgraded Amgen from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $324.00 to $318.00 in a research note on Wednesday, February 7th. Royal Bank of Canada upped their price objective on Amgen from $303.00 to $329.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Oppenheimer restated an “outperform” rating and set a $350.00 target price on shares of Amgen in a report on Thursday, February 1st. Finally, Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $264.00 to $320.00 in a report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $295.30.

Check Out Our Latest Report on Amgen

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.